Anti-CD223/LAG3 Polyclonal Antibody (HB613014)

Name: Anti-CD223/LAG3 Polyclonal Antibody
Brand: abinScience
SKU: HB613014
Price: 96 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

20ug
50ug
100ug

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.

HB613014

Description

Anti-CD223/LAG3 Polyclonal Antibody (HB613014) is a rabbit polyclonal antibody detecting CD223 in ELISA, IHC, WB. Suitable for Human.

Highlights

●Affinity Purified — Minimal background and high purity for reliable results.
●Multi-Application — Validated across multiple applications.

Species reactivity

Human

Applications

ELISA, IHC, WB

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human CD223/LAG3 (Leu23-Leu450).

Target

FDC, LAG3, Lymphocyte activation gene 3 protein, CD223, sLAG-3, LAG-3

Purification

Purified by antigen affinity column.

Accession

P18627

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
ELISA	1:5000-1:20000
IHC	1:50-1:500
WB	1:500-1:2000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Background

Lymphocyte activation gene 3 protein (CD223/LAG3) is a ~57 kDa protein. Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells. Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation. Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1. CD223 is the therapeutic target of relatlimab (Opdualag).

1. Camisaschi, C. et al. (2010) Journal of immunology (Baltimore, Md. : 1950) 184, 6545-51. PMID: 20421648

2. Ming, Q. et al. (2022) Nature immunology 23, 1031-1041. PMID: 35761082

3. Huard, B. et al. (1994) European journal of immunology 24, 3216-21. PMID: 7805750

4. Huard, B. et al. (1996) European journal of immunology 26, 1180-6. PMID: 8647185

5. Wang, J. et al. (2019) Cell 176, 334-347.e12. PMID: 30580966

6. MacLachlan, BJ. et al. (2021) European journal of immunology 51, 331-341. PMID: 32920841

7. Petersen, J. et al. (2024) Science immunology 9, eads5122. PMID: 39671469

8. Huard, B. et al. (1995) European journal of immunology 25, 2718-21. PMID: 7589152

10. Jiang, Y. et al. (2025) Cell 188, 2354-2371.e18. PMID: 40101708

Note

For research use only.

Images

Western blot

Western blot analysis was performed using anti-CD223/LAG3 polyclonal antibody at 1ug/mL on recombinant CD223/LAG3 (Catalog No. HB613012).

References

Datasheet